Cancer Medicine (Jun 2021)

Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin

  • Myunhee Lee,
  • Woo‐Baek Chung,
  • Ji‐eun Lee,
  • Chan‐Seok Park,
  • Woo‐Chan Park,
  • Byung‐Joo Song,
  • Ho‐Joong Youn

DOI
https://doi.org/10.1002/cam4.3956
Journal volume & issue
Vol. 10, no. 12
pp. 3964 – 3973

Abstract

Read online

Abstract Background There is no proven primary preventive strategy for doxorubicin‐induced subclinical cardiotoxicity (DISC), especially among patients without a cardiovascular (CV) risk. We investigated the primary preventive effect on DISC of the concomitant use of angiotensin receptor blockers (ARBs) or beta‐blockers (BBs), especially among breast cancer patients without a CV risk. Methods A total of 385 patients who were scheduled for doxorubicin chemotherapy were screened. Among them, 195 patients of the study populations were included and were randomly divided into two groups [candesartan 4 mg q.d. vs. carvedilol 3.125 mg q.d.] and patients who were unwilling to take one of the medications were evaluated as controls. The primary outcomes were the incidence of early DISC (DISC developing within 6 months after chemotherapy), and late DISC (DISC developing only at least 12 months after chemotherapy). Result Compared with the control group (8 out of 43 patients (18.6%)), only the candesartan group (4 out of 82 patients (4.9%)) showed a significantly lower incidence of early DISC (p = 0.022). Compared with the control group, the candesartan group demonstrated a significantly reduced decrease in left ventricular ejection fraction (LVEF) throughout the study period [−1.0% vs. −3.00 (p < 0.001) at the first follow‐up, −1.10% vs. −3.40(p = 0.009) at the second follow‐up]. Conclusions Among breast cancer patients without a CV risk treated with doxorubicin‐containing chemotherapy, subclinical cardiotoxicity is prevalent and concomitant administration of low‐dose candesartan might be effective to prevent an early decrease in LVEF. Further large‐scale, randomized controlled trials will be needed to confirm our findings.

Keywords